← Back to Search

Anti-metabolites

Sapacitabine/decitabine (Part 1 - completed) for Myelodysplastic Syndrome

Phase 1 & 2
Waitlist Available
Research Sponsored by Cyclacel Pharmaceuticals, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Study Summary

This is a combination study to evaluate sapacitabine administered in alternating cycles with decitabine in previously untreated Acute Myeloid Leukemia (AML) or concomitantly with venetoclax in previously treated AML or MDS

Eligible Conditions
  • Myelodysplastic Syndrome
  • Acute Myeloid Leukemia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of patients who achieve a clinical benefit response including CR, CRp, PR and major HI
Secondary outcome measures
hospitalized days
overall survival
response duration
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: sapacitabine/venetoclax (Part 2 - recruiting)Experimental Treatment1 Intervention
sapacitabine will be administered concomitantly with venetoclax
Group II: Sapacitabine/decitabine (Part 1 - completed)Experimental Treatment1 Intervention
decitabine will be administered in alternating cycles with sapacitabine

Find a Location

Who is running the clinical trial?

Cyclacel Pharmaceuticals, Inc.Lead Sponsor
19 Previous Clinical Trials
2,414 Total Patients Enrolled
M.D. Anderson Cancer CenterOTHER
2,973 Previous Clinical Trials
1,789,256 Total Patients Enrolled
Hagop M Kantarjian, MDStudy ChairM.D. Anderson Cancer Center
4 Previous Clinical Trials
668 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)
2010. "Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01211457.
All > Acute Myeloid Leukemia > Aml
~4 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top